Harrow Health to Announce Second Quarter 2021 Financial Results on August 10, 2021GlobeNewsWire • 07/26/21
NovaBay Pharmaceuticals Partners with Harrow Health's ImprimisRx® to Promote Prescription AvenovaBusiness Wire • 07/19/21
Down 14% in 4 Weeks, Here's Why You Should You Buy the Dip in Harrow (HROW)Zacks Investment Research • 07/16/21
Harrow (HROW) Surges 12%: Is This an Indication of Further Gains?Zacks Investment Research • 06/23/21
Harrow Health Announces Closing of $20 Million Aggregate Principal Amount Offering of 8.625% Senior Notes Due 2026GlobeNewsWire • 06/17/21
Harrow Health Announces Pricing of $17.5 Million Aggregate Principal Amount Offering of 8.625% Senior Notes Due 2026GlobeNewsWire • 06/14/21
Harrow Health Announces Offering of $17.5 Million of 8.625% Senior Notes Due 2026 and “BB” Rating from Egan-JonesGlobeNewsWire • 06/14/21
Leading Peer-Reviewed Ophthalmic Journal Publishes Study on ImprimisRx's Proprietary Klarity-C® DropsGlobeNewsWire • 05/17/21
Harrow Health, Inc. (HROW) CEO Mark Baum on Q1 2021 Results - Earnings Call TranscriptSeeking Alpha • 05/11/21
Harrow Health Raises Approximately $11 Million in Sale of Series B Preferred StockGlobeNewsWire • 05/05/21
Harrow Health Announces Full Exercise and Closing of Option to Purchase Additional Senior NotesGlobeNewsWire • 05/05/21
Will Harrow Health (HROW) Report Negative Earnings Next Week? What You Should KnowZacks Investment Research • 05/04/21
Harrow Health to Announce First Quarter 2021 Financial Results on May 11, 2021GlobeNewsWire • 04/27/21
Harrow Health Announces Closing of $50 Million Offering of Senior Notes Due 2026GlobeNewsWire • 04/20/21
Harrow Health Announces Pricing of $50 Million Offering of Senior Notes Due 2026GlobeNewsWire • 04/15/21
Harrow Health Announces Offering of $25 Million Senior Notes Due 2026 and “BB” Rating from Egan-JonesGlobeNewsWire • 04/14/21
Harrow Health, Inc.'s (HROW) CEO Mark Baum on Q4 2020 Results - Earnings Call TranscriptSeeking Alpha • 03/09/21